| Micro-channel |
 |
|
|
|
|
|
| |
| Domestic innovative medicine first access to health insurance drug negotiations the embarrassing situation |
| |
| Author：中國銘鉉 企劃部 Release Time：2017-8-17 15:05:44 Number Browse：788 |
| |
On August 17, the medical network showed that the driving force of China's market and policy for innovative drugs was taking shape.
And in February 2017 edition of "eight years" health first innovation medicine into the directory, the recent people club department issued the second national drug negotiation results, yasuhiro miyata pharmaceutical lang mu as representative of domestic innovation for national health insurance for the first time use directory.
Jubilant time inside and outside of, such as lang mu domestic innovation medicine into the national health insurance b reimbursement drug directory, and the price to maximize protection, make the industry agreed that the policy level support for domestic drug innovation is clear, is conducive to lead the whole pharmaceutical industry innovation and development.
In fact, more views still suggest that this change is also partly a solution to China's health care reform, which provides a solution to the costs of health care, benefiting the people.
In any case, the sun is rising and the sun is shining through the many companies that are on the frontline of drug innovation.
Behind the innings of innovative drugs: rise
The final result of the much-anticipated second round of national health care negotiations has finally been unveiled.
On July 19, about 36 kinds of drugs should be brought into the national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue b range notice issued by the, will 36 kinds of drugs into the national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue (2017 edition) ", to pay for health care and synchronized to determine the drug standard.
Basic belongs to the expensive medicine drugs "these talks, half for tumor targeted drugs, such as the common tumor such as lung cancer, gastric cancer, disease of heart head blood-vessel, ophthalmology, are also included in this major diseases such as diabetes drug, compared to 2016 the average retail price, negotiate drug average decline reached 44%, the highest reached 70%, most of the imported drugs after negotiation payment standard market price is lower than the surrounding countries and regions, the result is encouraging." Shi lichen, founder of the third party medical service platform, maxwell house.
Specifically, the 36 medicines negotiated successfully included 31 western medicines and 5 intermediated drugs. Fifteen of 31 western medicines were treated for cancer, including common cancers such as lung cancer and stomach cancer. Other drugs are nephropathy, ophthalmology and rare diseases, including the most aggressive compaq eye injection since the launch.
Analysts, including Mr Shi, believe that the biggest bright spot in the outcome of this round of drug negotiations is the entry of homegrown innovative drugs, represented by Mr Lang.
It cannot be ignored that in recent years, domestic innovative drugs have become more and more powerful in the whole pharmaceutical industry. Yasuhiro miyata pharmaceutical industry independent research and development production of countries "major drug discovery special major science and technology achievements" lang mu is suitable for the treatment of retinal neovascularization, the drug officially listed in April 2014, 2016 to 476 million yuan, in the industry as a model of Chinese medicine marketing innovation.
"This also shows that our independent innovative drugs are more competitive and provide a lot of benefits for patients, both in terms of drug safety and price." "Said shi.
The awkward situation forced the innings
Since 2008, when the country "major drug discovery" since science and technology major projects implementation, focus on encouraging in the field of major diseases such as malignant tumor, cardiovascular autonomic development and technical transformation of a group of drugs, improve the national drug innovation system.
"Before the 2017 medicare catalog out, our country already has more than seven years did not update the directory, and in the seven years is also more local drug firms to independent research and development, increased investment in innovation medicine, market also emerged many competitive domestic innovation medicine, this also means that innovation medicine has in fact have a certain foundation in our country, especially the basis of wrestling with imported drug innovation." Medical industry analyst gan xiang said.
But the reality is that some of the innovative drugs that have been developed independently are not included in our health care catalogs, which makes them more likely to compete with similar imports of innovative drugs.
A number of industry insiders said that many drug companies give priority to with r&d driven nearly two years to make its life difficult, research and development need to invest a lot of new drug research and development costs, post-marketing drug firms hadn't, rapid market success; But to waiting and haunting a province province requests into the medical insurance directory, because a lot of innovative medicine main sales channel is the hospital system, not into the medical insurance directory it will be difficult to open the market, more difficult to form the sales.
In October 2016, by the Chinese chemical industry association, China association of pharmaceutical enterprise management and so on four big authoritative industry association, entrust the McKinsey, a consultancy, made a "build the sustainable development of China's pharmaceutical innovation ecosystem, the depth of the report, the detailed analysis of the past, present and future of China's innovation medicine; And clearly points out that, on a world scale, a single innovative drug research and development costs as much as an average of 1.3 billion yuan to 1.8 billion yuan, but innovation medicine listed after five years in China, the average annual sales is only 050 million yuan to 150 million yuan, most of the new drug research and development of economic returns and even negative. The cruel marketing reality makes the innovation drug enterprise very embarrassing, to a certain extent reduces the enthusiasm that the enterprise invests heavily to develop innovative medicine.
Many medical industry analysts believe that China has not formed a driving force for the market and policy of innovative drugs for a long time. "The overall competitiveness of the pharmaceutical industry in China will be boosted by drug research and development. Only by allowing the drug companies to feel the impetus from the policy will they further promote the active participation of drug companies." GanXiangShui.
|
| |
Previous article：The "statins" dominate the lipids: 7 varieties of the market
Next article：Domestic innovative medicine first access to health insurance drug negotiations the embarrassing situation
|
| |
|
|
